GlassScriptPhysician profile
Heather Tiffany Rosa
NPI 1356906598
$1,607.51
in general payments reported to CMS, 2019-2025
25 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $210 · 2022: $211 · 2023: $335 · 2024: $379 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $429.73 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $132.86 | 2021-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $130.50 | 2021-2025 | Farxiga |
| Immunitybio, INC. | $82.38 | 2025 | |
| Abbvie INC. | $77.63 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $77.57 | 2025 | |
| Daiichi Sankyo INC. | $64.42 | 2021-2024 | Injectafer |
| Vanda Pharmaceuticals INC. | $60.80 | 2023 | Fanapt, Hetlioz |
| Tactile Systems Technology INC | $57.70 | 2025 | Flexitouch Plus, Nimbl |
| Bayer Healthcare Pharmaceuticals INC. | $55.42 | 2022-2023 | |
| Indivior INC. | $52.86 | 2024-2025 | Sublocade |
| Pfizer INC. | $51.64 | 2022-2024 | |
| Glaxosmithkline, LLC. | $49.51 | 2022-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.26 | 2024-2025 | Jardiance, Tradjenta |
| Exact Sciences Corporation | $32.01 | 2025 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $30.40 | 2022-2025 | Austedo Xr |
| Sanofi-Aventis U.S. LLC | $28.45 | 2025 | |
| Ucb, INC. | $22.98 | 2024 | Nayzilam |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.21 | 2024 | Xifaxan |
| Verona Pharma, INC. | $21.67 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $20.21 | 2023 | Spravato |
| Amgen INC. | $17.27 | 2024 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $14.36 | 2021 | |
| Redhill Biopharma INC. | $14.09 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Rosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.